Compounded tirzepatide claims: what TikTok gets right and wrong

What did @paulanrilyn actually say?

She just started tirzepatide two to three days ago and had a severe night of vomiting that kept her up until 3:30 AM. She showed up to work still nauseous and exhausted, made a Walmart run for papaya enzymes, Pepto-Bismol, nausea medication, and pate, and admitted she's "really contemplating" whether to take her next dose. She also noted her appetite has dropped and she's been forcing herself to eat.

That's a pretty candid account of early GLP-1 side effects. She's not diagnosing anything, not claiming tirzepatide cured her, not recommending doses. She's just describing what happened to her body and asking for community tips. That kind of honesty is actually more useful to prospective users than most polished brand content.

Does the science back this up?

Yes, and then some. Nausea and vomiting in the first days to weeks of tirzepatide use are among the most well-documented side effects in the clinical literature. This is not anecdote, it's pharmacology.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) reported nausea in roughly 30-40% of participants across the 5 mg, 10 mg, and 15 mg tirzepatide dose groups, with vomiting occurring in 15-25% of patients. These effects were most pronounced early in treatment and during dose escalation. A similar pattern was documented in the SURPASS-2 trial (Frías et al., 2021, NEJM) comparing tirzepatide to semaglutide.

The mechanism is not mysterious. Tirzepatide activates both GIP and GLP-1 receptors. GLP-1 receptor activation slows gastric emptying significantly, which is part of why appetite drops but also why food sitting in the stomach longer causes nausea. The brain's area postrema, which lacks a blood-brain barrier, also responds to GLP-1 receptor agonism, contributing to centrally mediated nausea (Drucker, 2022, Cell Metabolism).

What she experienced is textbook early-phase GLP-1 side effects. The severity she describes, vomiting most of the night, is on the higher end but not outside what the trials documented.

What did they get wrong (or right)?

She got most of it right by not overstating anything. She didn't claim this was dangerous, she didn't say the drug was defective, and she didn't tell her audience to quit. She correctly identified that her appetite has decreased, which aligns with tirzepatide's known mechanism.

The one area worth flagging is the Walmart remedy haul. Papaya enzymes have no peer-reviewed evidence for managing GLP-1-induced nausea. They're marketed for general digestion, but that's not the same problem. Pepto-Bismol (bismuth subsalicylate) has some data for nausea and upset stomach, but it can interact with certain medications and isn't the first-line recommendation in this context.

The actual clinical guidance for GLP-1 nausea management centers on eating smaller, blander meals, avoiding high-fat or high-sugar foods that further slow gastric emptying, staying upright after eating, and, when needed, prescribed antiemetics like ondansetron. She found her own path to some of those answers, but the papaya enzyme recommendation circulating in GLP-1 communities is not backed by evidence.

Forcing herself to eat despite no appetite is actually the right instinct. Adequate protein intake during GLP-1 therapy is critical for preserving lean muscle mass during weight loss (Wilding et al., 2021, NEJM, semaglutide data, with analogous principles for tirzepatide).

What should you actually know?

If you're starting tirzepatide and experiencing what she described, the single most important thing to understand is that this is a dose-response and timing phenomenon, not a sign the medication isn't working or that something has gone seriously wrong.

Nausea peaks early in treatment and typically improves within the first few weeks as the body adjusts. The standard titration schedule, starting at the lowest dose and moving up slowly, exists precisely to reduce this side effect burden. If nausea is severe enough to cause significant vomiting, dehydration, or inability to work, that is a signal to contact your prescriber before taking the next dose, not to white-knuckle through it or crowdsource a remedy on TikTok.

The question of whether to take the next dose is a clinical decision, not a community vote. A prescriber can adjust timing, extend the time at a lower dose, or prescribe an antiemetic. These are standard tools. If she's on a compounded tirzepatide formulation, the same guidance applies, though her prescribing provider should be her first call regardless of source.

• Staying hydrated matters more than forcing solid food if vomiting is severe.
• Small, low-fat, low-fiber meals reduce gastric emptying delay and tend to be better tolerated.
• Ginger in any form (tea, capsules) has modest evidence for nausea reduction and is generally safe (Ernst and Pittler, 2000, British Journal of Anaesthesia).